First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma | Naviance

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

LEARN MORE

Recent Posts

Colon Cancer Screening: What You Need to Know Detecting Early-Stage Cancers with a New Blood Test Measuring Epigenetic Instability Oral Bacterium May Promote Breast Cancer Development and Spread Extra Copies of Chromosome 1q May Drive Pancreatic Cancer How Bacteria May Promote Breast Cancer Growth of Spreading Pancreatic Cancer Fueled By “Under-Appreciated” Epigenetic Changes Updated Guidelines Standardize How Tumor Response Is Measured After Surgery Running the Distance: Patient Teams with Johns Hopkins Medicine Dermatologists to Treat, Understand Rare Hereditary Cancer Syndrome New Technology: MRI-guided Focused Ultrasound for Prostate Cancer